On October 24, 2024, Endpoints News reported that AI-powered biotech company Fable Therapeutics, a University of Toronto spinoff, raised a total of $53.5 million from combined Seed and Series A financings led by Versant Ventures and DCVC Bio. Fable Therapeutics is optimizing proprietary AI technology to produce protein therapies that could improve weight loss and related health issues. Fable CEO Geoff MacKay said the capital raised is intended to fund the company into 2026.

A Wilson Sonsini Goodrich & Rosati team led by Karen Deschaine and Phil McGill advised Fable Therapeutics on these transactions.

For more information, please see coverage from Endpoints News.